OBJECTIVE: To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer. BACKGROUND: Induction chemotherapy has become an accepted choice for the treatment of locally advanced adenocarcinoma of the esophagus and the esophagogastric junction. It has been shown that early assessment of metabolic response using positron emission tomography predicts response to chemotherapy. Metabolic response has also been revealed to be an independent prognostic factor. METHODS: Surgical risk and outcome in metabolic responders were compared with those in nonresponders. The study design predefined a 12-week multicourse preoperative chemotherapy regimen in metabolic responders. In contrast, chemotherapy was stopped after a 2-week induction period in metabolic nonresponders. All patients were scheduled for surgical resection. RESULTS: Of 110 evaluable patients, 50 metabolic responders and 54 nonresponders underwent resection. Postoperative complications occurred in 34%. Two patients (1.8%) died. There were no significant differences between responders and nonresponders in terms of postoperative morbidity and mortality. Major histologic remissions were seen in 58% of metabolic responders. Metabolic responders had an increased chance of having an R0 resection (96% vs. 74%; P=0.002) and a decreased risk of developing hematogenous or distant lymphatic recurrence (32% vs. 54%, P=0.019). This translated into better recurrence-free and overall survival. CONCLUSIONS: Induction chemotherapy and early metabolic response assessment is a new concept in the treatment of locally advanced Barrett cancer. Metabolic responders undergoing multicourse preoperative chemotherapy have a good prognosis. The best treatment strategy for nonresponders remains to be defined.
OBJECTIVE: To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer. BACKGROUND: Induction chemotherapy has become an accepted choice for the treatment of locally advanced adenocarcinoma of the esophagus and the esophagogastric junction. It has been shown that early assessment of metabolic response using positron emission tomography predicts response to chemotherapy. Metabolic response has also been revealed to be an independent prognostic factor. METHODS: Surgical risk and outcome in metabolic responders were compared with those in nonresponders. The study design predefined a 12-week multicourse preoperative chemotherapy regimen in metabolic responders. In contrast, chemotherapy was stopped after a 2-week induction period in metabolic nonresponders. All patients were scheduled for surgical resection. RESULTS: Of 110 evaluable patients, 50 metabolic responders and 54 nonresponders underwent resection. Postoperative complications occurred in 34%. Two patients (1.8%) died. There were no significant differences between responders and nonresponders in terms of postoperative morbidity and mortality. Major histologic remissions were seen in 58% of metabolic responders. Metabolic responders had an increased chance of having an R0 resection (96% vs. 74%; P=0.002) and a decreased risk of developing hematogenous or distant lymphatic recurrence (32% vs. 54%, P=0.019). This translated into better recurrence-free and overall survival. CONCLUSIONS: Induction chemotherapy and early metabolic response assessment is a new concept in the treatment of locally advanced Barrett cancer. Metabolic responders undergoing multicourse preoperative chemotherapy have a good prognosis. The best treatment strategy for nonresponders remains to be defined.
Authors: Nishant Agrawal; Yuchen Jiao; Chetan Bettegowda; Susan M Hutfless; Yuxuan Wang; Stefan David; Yulan Cheng; William S Twaddell; Nyan L Latt; Eun J Shin; Li-Dong Wang; Liang Wang; Wancai Yang; Victor E Velculescu; Bert Vogelstein; Nickolas Papadopoulos; Kenneth W Kinzler; Stephen J Meltzer Journal: Cancer Discov Date: 2012-08-09 Impact factor: 39.397
Authors: Kfir Ben-David; George A Sarosi; Juan C Cendan; Drew Howard; Georgios Rossidis; Steven N Hochwald Journal: Surg Endosc Date: 2011-07-27 Impact factor: 4.584
Authors: Sandra Rauser; Rupert Langer; Sebastian Tschernitz; Peter Gais; Uta Jütting; Marcus Feith; Heinz Höfler; Axel Walch Journal: BMC Cancer Date: 2010-11-05 Impact factor: 4.430
Authors: Matthias Schmidt; Elfriede Bollschweiler; Markus Dietlein; Stefan P Mönig; Carsten Kobe; Daniel Vallböhmer; Daniel Vallboehmer; Wolfgang Eschner; Arnulf Hölscher; Harald Schicha Journal: Eur J Nucl Med Mol Imaging Date: 2008-12-19 Impact factor: 9.236